Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

Autor: Albert C Ludolph, Joachim Schuster, Johannes Dorst, Luc Dupuis, Jens Dreyhaupt, Jochen H Weishaupt, Jan Kassubek, Ulrike Weiland, Susanne Petri, Thomas Meyer, Julian Grosskreutz, Berthold Schrank, Matthias Boentert, Alexander Emmer, Andreas Hermann, Daniel Zeller, Johannes Prudlo, Andrea S Winkler, Torsten Grehl, Michael T Heneka, Siw Wollebæk Johannesen, Bettina Göricke, Andreas Funke, Dagmar Kettemann, Robert Meyer, Kai Gruhn, Peter Schwenkreis, Philipp Stude, Delia Kurzwelly, Alexander Storch, Nicole Richter, Tobias Frank, Katharina Hein, Frank Hanisch, Dagmar Hanke, Torsten Kraya, Andreas Posa, Martina Romanakova, Susanne Schilling, Susanne Abdulla, Sebastian Böselt, Claas Janssen, Imken Lange, Xenia Kobeleva, Sonja Körner, Katja Kollewe, Alma Osmanovic, Nicole Scharn, Klaus J Rath, Christiane Dahms, Anne Gunkel, Bianka Heiling, Thomas Ringer, Uta Smesny, Sarah Baumeister, Achim Berthele, Sarah Bublitz, Esra Akova-Öztürk, Bianca Stubbe-Dräger, Alexandra Rahmann, Charlotte Young, Peter Young, Dobri Baldaranov, Ulrich Bogdahn, Andrei Khomenko, Wilhelm Schulte-Mattler, Christina Stadler, Susanne Husung, Simone Tesar, Nigar Dargah-Zaden, Christina Last, Eva Langer, Ann-Sophie Lauenstein, Eckard Lensch, Carolyn Mc Farlane, Heike Fischer-Brasse, Klara Orbán, Bertold Schrank, Sonja Schürger, Stephan Klebe, Peter Kraft, Thomas Musacchio, Carola Seiler

Publikováno v: The Lancet Neurology
The Lancet Neurology, Elsevier, 2018, 17 (8), pp.681-688. ⟨10.1016/S1474-4422(18)30176-5⟩
The Lancet Neurology, 2018, 17 (8), pp.681-688. ⟨10.1016/S1474-4422(18)30176-5⟩

International audience; Background: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral scleros

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70e9f6bbf70e7d2a063a95b23e7ffaa
https://doi.org/10.1016/s1474-4422(18)30176-5

6-Hydroxydopamine leads to T2 hyperintensity, decreased claudin-3 immunoreactivity and altered aquaporin 4 expression in the striatum

Autor: Adriane Gröger, Eva Küppers, Britta Wachter, Bernd J. Pichler, Andreas von Ameln-Mayerhofer, Rüdiger Sadler, Sonja Schürger, Hans-Joachim Wagner, Anna Speidel, Andreas Schmid, Jens Rolinger, Daniela Berg

Publikováno v: Behavioural brain research 232(1), 148-158 (2012). doi:10.1016/j.bbr.2012.04.005

The neurotoxin 6-hydroxydopamine (6-OHDA) is frequently used in animal models to mimic Parkinson's disease. Imaging studies describe hyperintense signalling in regions close to the site of the 6-OHDA injection in T2-weighted (T2w) magnetic resonance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::827fea2ed870e27394eb4ad1b9329853
https://doi.org/10.1016/j.bbr.2012.04.005

AMBIANTAL ARCHITECTURE − Defining the role of water in the aesthetic experience of sensitive architectural ambiances.

Autor: Lescop, L., Kępczyńska-Walczak, A., Sioui, Gregory Brais

Publikováno v: SHS Web of Conferences; 2019, Vol. 64, p1-9, 9p